- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07939854
Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage
A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage
This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Yong Cao
- Telefoonnummer: +86 13601362306
- E-mail: caoyong@bjth.org
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100070
- Werving
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Yong Cao
- Telefoonnummer: +86 13601362306
- E-mail: caoyong@bjth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years and <80 years.
- Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
- Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
- A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
- Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
- Randomization initiated between 6 and 12 hours after the diagnostic CT.
- Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.
Exclusion Criteria:
- Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
- Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
- The predominant portion of the hematoma involves the midbrain or medulla.
- Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
- Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
- Previous history of brainstem hemorrhage.
- Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
- An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
- CT evidence indicating a high risk of rebleeding, including a spot sign.
- Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
- Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
- Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
- Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
- Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
- Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
- Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
- Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
- Known hypersensitivity to tenecteplase.
- Previous participation in this study with completed randomization.
- Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
- Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
- Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
- Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
- Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
- Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
- The participant requests conservative treatment or conventional open microsurgical treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Stereotactic Aspiration Combined With Tenecteplase
Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment. |
Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization. Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.
Andere namen:
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
|
Actieve vergelijker: Standard Medical Treatment
|
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Participants With GCS Score >8
Tijdsspanne: 90 days after randomization
|
Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. |
90 days after randomization
|
|
All-Cause Mortality
Tijdsspanne: Within 30 days after randomization.
|
Proportion of participants who die from any cause within 30 days after randomization. |
Within 30 days after randomization.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
7-Day All-Cause Mortality
Tijdsspanne: Within 7 days
|
Within 7 days
|
|
Symptomatic Rebleeding
Tijdsspanne: Within 72 hours after tenecteplase administration
|
Within 72 hours after tenecteplase administration
|
|
Intracranial Bacterial Infection
Tijdsspanne: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
Tijdsspanne: Within 30 days
|
Within 30 days
|
|
Adverse Events (AEs)
Tijdsspanne: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
Tijdsspanne: Within 365 days
|
Within 365 days
|
|
Adverse Events (AEs)
Tijdsspanne: Within 365 days
|
Within 365 days
|
|
Proportion With GCS Increase ≥3 Points
Tijdsspanne: 30 days
|
30 days
|
|
Proportion With Recovery of Consciousness
Tijdsspanne: 30 days
|
30 days
|
|
Proportion With mRS 0-3
Tijdsspanne: 90 days
|
90 days
|
|
Proportion With mRS 0-3
Tijdsspanne: 365 days
|
365 days
|
|
Change in GCS Score Over Time
Tijdsspanne: From baseline through 90 days after randomization
|
From baseline through 90 days after randomization
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LX-2026-0001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .